Press release from GlobeNewswire (a Nasdaq OMX company)
Auxilium Pharmaceuticals, Inc. [AUXL] to Ring The NASDAQ Stock Market Opening Bell
Tuesday, February 25, 2014
Auxilium Pharmaceuticals, Inc. [AUXL] to Ring The NASDAQ Stock Market Opening Bell07:00 EST Tuesday, February 25, 2014
ADVISORY, Feb. 25, 2014 (GLOBE NEWSWIRE) --
Auxilium Pharmaceuticals, Inc. [AUXL], a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Adrian Adams, Chief Executive Officer and President will ring the Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Wednesday, February 26, 2014 – 9:15 a.m. to 9:30 a.m. ET
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
A LiveStream of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Auxilium Pharmaceuticals, Inc. [AUXL]:
Auxilium Pharmaceuticals, Inc. is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences. With a broad range of first- and second-line products across multiple indications, Auxilium is an emerging leader in the men's healthcare area and has strategically expanded its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. Auxilium now has a broad portfolio of 12 approved products. Among other products in the U.S., Auxilium markets Edex® (alprostadil for injection), an injectable treatment for erectile dysfunction, Osbon ErecAid®, the leading device for aiding erectile dysfunction, STENDRA™ (avanafil), an oral erectile dysfunction therapy, Testim® (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL® (testosterone pellets) a long-acting implantable testosterone replacement therapy, XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease and XIAFLEX for the treatment of Dupuytren's contracture. The Company also has programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite. Auxilium's mission is to improve the lives of patients throughout the world by successfully identifying, developing and commercializing innovative specialty biopharmaceutical products. To learn more, please visit www.Auxilium.com.
About NASDAQ OMX Group :
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and approximately 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,300 listed companies with a market value of over $7 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.